Table 1.
Clinical profile and iNKT cell data from non-index participants 1 and 2 at baseline and 6 weeks following commencement of GLP-1 analogue treatment
| Variable | Participant 1 | Participant 2 |
|---|---|---|
| Age (years) | 48 | 49 |
| Sex | Male | Male |
| Diabetes duration (years) | 2 | 4 |
| Co-morbidities | ||
| Hypertension | Yes | Yes |
| Dyslipidaemia | No | Yes |
| Osteoarthritis | Yes | No |
| Relevant medications | ||
| Metformin | Yes | Yes |
| Aspirin | Yes | Yes |
| Diuretic | Yes | No |
| Calcium channel blocker | Yes | Yes |
| ACE inhibitor | No | Yes |
| Statin | No | Yes |
| Psoriasis treatmenta | No | No |
| Body weight (kg) | ||
| Baseline | 159.1 | 137.8 |
| 6 weeks | 154.0 | 131.6 |
| BMI (kg/m2) | ||
| Baseline | 48.0 | 43.0 |
| 6 weeks | 46.5 | 41.1 |
| HbA1c, % (mmol/mol) | ||
| Baseline | 5.7 (38) | 5.9 (40) |
| 6 weeks | 5.6 (37) | 5.8 (39) |
| PASI | ||
| Baseline | 13.2 | 4.8 |
| 6 weeks | 10.8 | 3.8 |
| iNKT cells (% of lymphocytes) | ||
| Skin | ||
| Baseline | 2.16 | 0.32 |
| 6 weeks | 0.07 | 0.00 |
| Blood | ||
| Baseline | 0.15 | 0.16 |
| 6 weeks | 0.6 | 0.57 |
aTopical or oral treatment within previous 6 months